Evidence map›Paper›PMID 26017033›Full record

ArticleLeukemia2015

Protracted dormancy of pre-leukemic stem cells.

A M Ford, M B Mansur, C L Furness, F W van Delft, J Okamura, T Suzuki, H Kobayashi, Y Kaneko, M Greaves

Abstract read
In one paragraph

Article in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Cytokines, breast cancer stem cells (BCSCs) and chemoresistance.Clinical and translational medicine · 2018
    Review
  9. Homologue-specific chromosome sequencing characterizes translocation junctions and permits allelic assignment.DNA research : an international journal for rapid publication of reports on genes and genomes · 2018
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

A M FordCentre for Evolution and Cancer, The Institute of Cancer Research, London, Sutton, UK.
M B MansurCentre for Evolution and Cancer, The Institute of Cancer Research, London, Sutton, UK.
C L FurnessCentre for Evolution and Cancer, The Institute of Cancer Research, London, Sutton, UK.
F W van DelftNewcastle Cancer Centre, NICR, Newcastle, UK.
J OkamuraDepartment of Pediatrics, National Kyushu Cancer Centre, Minami-ku, Japan.
T SuzukiDepartment of Hematology, Saitama Cancer Centre, Ina, Japan.
H KobayashiDepartment of Hematology, Saitama Cancer Centre, Ina, Japan.
Y KanekoDepartment of Hematology, Saitama Cancer Centre, Ina, Japan.
M GreavesCentre for Evolution and Cancer, The Institute of Cancer Research, London, Sutton, UK.

Funding

Wellcome Trust 105104Wellcome Trust 105104/Z/14/Z
6 · The paper itself

Abstract

Cancer stem cells can escape therapeutic killing by adopting a quiescent or dormant state. The reversibility of this condition provides the potential for later recurrence or relapse, potentially many years later. We describe the genomics of a rare case of childhood BCR-ABL1-positive, B-cell precursor acute lymphoblastic leukemia that relapsed, with an acute myeloblastic leukemia immunophenotype, 22 years after the initial diagnosis, sustained remission and presumed cure. The primary and relapsed leukemias shared the identical BCR-ABL1 fusion genomic sequence and two identical immunoglobulin gene rearrangements, indicating that the relapse was a derivative of the founding clone. All other mutational changes (single-nucleotide variant and copy number alterations) were distinct in diagnostic or relapse samples. These data provide unambiguous evidence that leukemia-propagating cells, most probably pre-leukemic stem cells, can remain covert and silent but potentially reactivatable for more than two decades.

Indexed as

Child, PreschoolExomeFusion Proteins, bcr-ablGene DosageGene RearrangementGenes, ImmunoglobulinHumansIkaros Transcription FactorMaleNeoplastic Stem CellsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaBCR-ABL1 fusion protein, humanFusion Proteins, bcr-ablIkaros Transcription FactorIKZF1 protein, human

Identifiers

PMID26017033
PMCPMC4564945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.